30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

C4 Therapeutics Inc (CCCC)

Track

Recent insider trading at C4 Therapeutics Inc. shows a net sell-off over the last 90 days, with total sales exceeding $350,000. Notably, an officer and a former section 16 officer made proposed sales. The company's stock has seen significant positive performance, up over 61% in the past 90 days, reaching near its 52-week high.
Stock chart
Ticker: CCCC Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Mark Mossler
Former Section 16 Officer
1 sale — total 35,485 USD
Proposed sale 27 May 2026
Value US$4,691,011.59 | Price 425.69 | Shares 96,148
Proposed sale 9 Mar 2026
Value US$83,102.43 | Price 485.38 | Shares 58,191
Sale 16 Jan 2026
Value US$22,200.00 | Price 2.22 | Shares 10,000
Planned sale 18 Feb 2025
Value US$2,107.35 | Price 3.15 | Shares 669
Planned sale 14 Feb 2025
Value US$1,543.50 | Price 3.15 | Shares 490
Proposed sale 18 Nov 2024
Value US$54,531.75 | Price 4.19 | Shares 13,000
Proposed sale 18 Oct 2024
Value US$83,320.51 | Price 6.41 | Shares 13,000
Proposed sale 11 Oct 2024
Value US$46,061.18 | Price 5.38 | Shares 8,561
Buy 8 Feb 2023
Value US$31,735.20 | Price 5.60 | Shares 5,667
Buy 12 Apr 2022
Value US$84,000.00 | Price 8.40 | Shares 10,000
Planned sale 4 Jan 2022
Value US$34,420.48 | Price 32.66 | Shares 1,054
Planned sale 4 Jan 2022
Value US$440,547.17 | Price 31.59 | Shares 13,946
Planned sale 17 Dec 2021
Value US$22,838.75 | Price 30.25 | Shares 755
Planned sale 19 Nov 2021
Value US$30,283.05 | Price 40.11 | Shares 755
Planned sale 15 Oct 2021
Value US$33,929.70 | Price 44.94 | Shares 755
Planned sale 1 Oct 2021
Value US$235,118.77 | Price 45.99 | Shares 5,112
Planned sale 1 Oct 2021
Value US$370,563.30 | Price 45.32 | Shares 8,176
Planned sale 1 Oct 2021
Value US$75,756.34 | Price 44.25 | Shares 1,712
Planned sale 27 Sep 2021
Value US$65,604.01 | Price 50.04 | Shares 1,311
Planned sale 27 Sep 2021
Value US$26,969.03 | Price 50.04 | Shares 539
Planned sale 13 Sep 2021
Value US$166,743.42 | Price 50.07 | Shares 3,330
Planned sale 13 Sep 2021
Value US$166,730.44 | Price 50.07 | Shares 3,330
Planned sale 10 Sep 2021
Value US$66,009.90 | Price 50.01 | Shares 1,320
Planned sale 10 Sep 2021
Value US$61,500.98 | Price 50.00 | Shares 1,230
Planned sale 10 Sep 2021
Value US$625,000.00 | Price 50.00 | Shares 12,500
Planned sale 2 Aug 2021
Value US$191,606.29 | Price 45.01 | Shares 4,257
Planned sale 29 Jul 2021
Value US$510,167.61 | Price 45.00 | Shares 11,336
Planned sale 29 Jul 2021
Value US$675,000.00 | Price 45.00 | Shares 15,000
Planned sale 16 Jul 2021
Value US$28,214.35 | Price 37.37 | Shares 755
Planned sale 18 Jun 2021
Value US$28,078.45 | Price 37.19 | Shares 755
Planned sale 21 May 2021
Value US$28,025.60 | Price 37.12 | Shares 755
Planned sale 5 Apr 2021
Value US$413,407.44 | Price 38.00 | Shares 10,879
Planned sale 5 Apr 2021
Value US$153,128.53 | Price 37.16 | Shares 4,121
Buy 6 Oct 2020
Value US$24,985.00 | Price 19.00 | Shares 1,315
Buy 6 Oct 2020
Value US$95,570.00 | Price 19.00 | Shares 5,030
Buy 6 Oct 2020
Value US$99,997.00 | Price 19.00 | Shares 5,263
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-28 2026-05-27 PrS Proposed sale
Mark Mossler

Former Section 16 Officer

Officer
96,148
425.69
US$4,691,012 		96,148 425.69 US$4,691,012
2026-03-09 2026-03-09 PrS Proposed sale
JOLIE M SIEGEL

Officer

Officer
58,191
485.38
US$83,102 		58,191 485.38 US$83,102
2026-01-16 2026-01-16 S Sale
1.5
REYNO LEONARD

Chief Medical Officer

Officer
6,762 -31.2%
375.95
US$940,433 		6,762 -31.2% 375.95 US$940,433
2025-02-18 2025-02-18 PlS Planned sale
Boyle Scott N

Chief Business Officer

Officer
669 -0.6%
3.15
US$2,107 		669 -0.6% 3.15 US$2,107
2025-02-18 2025-02-14 PlS Planned sale
Boyle Scott N

Chief Business Officer

Officer
490 -0.4%
3.15
US$1,544 		490 -0.4% 3.15 US$1,544
2024-11-18 2024-11-18 PrS Proposed sale
Salter Malcolm

Director

Non-Executive Director
13,000
4.19
US$54,532 		13,000 4.19 US$54,532
2024-10-18 2024-10-18 PrS Proposed sale
Salter Malcolm

Director

Non-Executive Director
13,000
6.41
US$83,321 		13,000 6.41 US$83,321
2024-10-11 2024-10-11 PrS Proposed sale
Salter Malcolm

Director

Non-Executive Director
8,561
5.38
US$46,061 		8,561 5.38 US$46,061
2023-02-10 2023-02-08 B Purchase
0.5
Koppikar Utpal
Non-Executive Director
5,667 +inf%
5.60
US$31,735 		5,667 +inf% 5.60 US$31,735
2022-04-12 2022-04-12 B Purchase
2.3
Hirsch Andrew

President & CEO

Executive Director
10,000 +inf%
8.40
US$84,000 		10,000 +inf% 8.40 US$84,000
2022-01-05 2022-01-04 PlS Planned sale
1.7
Crystal Adam

Chief Medical Officer

Officer
1,054 -6.6%
32.66
US$34,420 		1,054 -6.6% 32.66 US$34,420
2022-01-05 2022-01-04 PlS Planned sale
1.7
Crystal Adam

Chief Medical Officer

Officer
13,946 -46.5%
31.59
US$440,547 		13,946 -46.5% 31.59 US$440,547
2021-12-17 2021-12-17 PlS Planned sale
Salter Malcolm
Non-Executive Director
755 -6.4%
30.25
US$22,839 		755 -6.4% 30.25 US$22,839
2021-11-19 2021-11-19 PlS Planned sale
Salter Malcolm
Non-Executive Director
755 -6.1%
40.11
US$30,283 		755 -6.1% 40.11 US$30,283
2021-10-15 2021-10-15 PlS Planned sale
Salter Malcolm
Non-Executive Director
755 -5.7%
44.94
US$33,930 		755 -5.7% 44.94 US$33,930
2021-10-05 2021-10-01 PlS Planned sale
1.7
Crystal Adam

Chief Medical Officer

Officer
5,112 -100.0%
45.99
US$235,119 		5,112 -100.0% 45.99 US$235,119
2021-10-05 2021-10-01 PlS Planned sale
1.7
Crystal Adam

Chief Medical Officer

Officer
8,176 -61.5%
45.32
US$370,563 		8,176 -61.5% 45.32 US$370,563
2021-10-05 2021-10-01 PlS Planned sale
1.7
Crystal Adam

Chief Medical Officer

Officer
1,712 -11.4%
44.25
US$75,756 		1,712 -11.4% 44.25 US$75,756
2021-09-29 2021-09-27 PlS Planned sale
Prokupets Elena
Non-Executive Director
1,311 -0.3%
50.04
US$65,604 		1,311 -0.3% 50.04 US$65,604
2021-09-29 2021-09-27 PlS Planned sale
Prokupets Elena
Non-Executive Director
539 -1.7%
50.04
US$26,969 		539 -1.7% 50.04 US$26,969
2021-09-14 2021-09-13 PlS Planned sale
Prokupets Elena
Non-Executive Director
3,330 -0.6%
50.07
US$166,743 		3,330 -0.6% 50.07 US$166,743
2021-09-14 2021-09-13 PlS Planned sale
Prokupets Elena
Non-Executive Director
3,330 -3.8%
50.07
US$166,730 		3,330 -3.8% 50.07 US$166,730
2021-09-14 2021-09-10 PlS Planned sale
Prokupets Elena
Non-Executive Director
1,320 -0.2%
50.01
US$66,010 		1,320 -0.2% 50.01 US$66,010
2021-09-14 2021-09-10 PlS Planned sale
Prokupets Elena
Non-Executive Director
1,230 -1.4%
50.00
US$61,501 		1,230 -1.4% 50.00 US$61,501
2021-09-14 2021-09-10 PlS Planned sale
Siegel Jolie

Chief Legal Officer

Officer
12,500 -100.0%
50.00
US$625,000 		12,500 -100.0% 50.00 US$625,000
2021-08-02 2021-08-02 PlS Planned sale
Prokupets Elena
Non-Executive Director
4,257 -4.0%
45.01
US$191,606 		4,257 -4.0% 45.01 US$191,606
2021-08-02 2021-07-29 PlS Planned sale
Prokupets Elena
Non-Executive Director
11,336 -9.6%
45.00
US$510,168 		11,336 -9.6% 45.00 US$510,168
2021-08-02 2021-07-29 PlS Planned sale
1.7
Crystal Adam

Chief Medical Officer

Officer
15,000 -100.0%
45.00
US$675,000 		15,000 -100.0% 45.00 US$675,000
2021-07-19 2021-07-16 PlS Planned sale
Salter Malcolm
Non-Executive Director
755 -5.0%
37.37
US$28,214 		755 -5.0% 37.37 US$28,214
2021-06-21 2021-06-18 PlS Planned sale
Salter Malcolm
Non-Executive Director
755 -4.8%
37.19
US$28,078 		755 -4.8% 37.19 US$28,078
2021-05-24 2021-05-21 PlS Planned sale
Salter Malcolm
Non-Executive Director
755 -4.6%
37.12
US$28,026 		755 -4.6% 37.12 US$28,026
2021-04-06 2021-04-05 PlS Planned sale
1.7
Crystal Adam

Chief Medical Officer

Officer
10,879 -100.0%
38.00
US$413,407 		10,879 -100.0% 38.00 US$413,407
2021-04-06 2021-04-05 PlS Planned sale
1.7
Crystal Adam

Chief Medical Officer

Officer
4,121 -27.5%
37.16
US$153,129 		4,121 -27.5% 37.16 US$153,129
2020-10-06 2020-10-06 B Purchase
Salter Malcolm
Non-Executive Director
1,315 +9.0%
19.00
US$24,985 		1,315 +9.0% 19.00 US$24,985
2020-10-06 2020-10-06 B Purchase
3.3
COHEN MARC A
Non-Executive Director Large shareholder
5,030 +inf%
19.00
US$95,570 		5,030 +inf% 19.00 US$95,570
2020-10-06 2020-10-06 B Purchase
MCKEE WILLIAM

Chief Financial Officer

Officer
5,263 +inf%
19.00
US$99,997 		5,263 +inf% 19.00 US$99,997
Explore more

More insider trading research around C4 Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America